ArticlePolymers2025
Discovery and Development of One Monomer Molecularly Imprinted Polymers (OMNiMIPs).
Article in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecularly imprinted polymers (MIPs) are polymeric receptors for a targeted template molecule that are traditionally formed using a combination of functional monomers and crosslinkers. While investigating novel crosslinkers for MIPs, one of these (2-(methacryloylamino)ethyl-2-methylacrylate (referred to as N,O-bismethacryloyl ethanolamine or "NOBE")) performed better when used alone versus in combination with other monomers. This introduced the concept of one monomer molecularly imprinted polymers, given the acronym OMNiMIPs, and prompted studies provided in this report that clarify OMNiMIPs have fundamental differences compared to traditionally formulated MIPs. Enantioselectivity studies using BOC-L-tyrosine as a standard template showed that NOBE OMNiMIPs afforded higher-performing MIPs compared with traditional MIPs, have significantly higher binding capacities, and have an internal hydrogen-bonded crosslinking structure that contributes to the morphological stability of the binding site structure. Based on the adventitious discovery of NOBE OMNiMIPs, new analogs based on the NOBE structure were developed and evaluated for further enhancement of molecular recognition performance and novel capabilities of OMNiMIPs. While the majority of the new OMNiMIPs exhibited enantiomeric selectivity toward BOC-L-tyr, improvements were not observed compared with NOBE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.